Senators Push for Action Against Misleading Drug Ads on Social Media

Lawmakers have criticized the FDA for the lack of updates on its guidance for prescription-drug promotion on social media over the past decade. They argue that the absence of updated guidance has allowed for potential misinformation and misleading advertising to thrive on these platforms. The criticism highlights the need for the FDA to keep up with the evolving landscape of social media and ensure that regulations are in place to protect consumers and promote accurate information.